Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.

MLA

Kläsener, Kathrin, et al. “Targeting CD38 with Monoclonal Antibodies Disrupts Key Survival Pathways in Paediatric Burkitt’s Lymphoma Malignant B Cells.” Clinical & Translational Immunology, vol. 13, no. 10, Oct. 2024, pp. 1–17. EBSCOhost, https://doi.org/10.1002/cti2.70011.

APA

Kläsener, K., Herrmann, N., Håversen, L., Sundell, T., Sundqvist, M., Lundqvist, C., Manna, P. T., Jonsson, C. A., Visentini, M., Ljung Sass, D., McGrath, S., Grimstad, K., Aranburu, A., Mellgren, K., Fogelstrand, L., Forsman, H., Ekwall, O., Borén, J., Gjertsson, I., & Reth, M. (2024). Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt’s lymphoma malignant B cells. Clinical & Translational Immunology, 13(10), 1–17. https://doi.org/10.1002/cti2.70011

Chicago

Kläsener, Kathrin, Nadja Herrmann, Liliana Håversen, Timothy Sundell, Martina Sundqvist, Christina Lundqvist, Paul T Manna, et al. 2024. “Targeting CD38 with Monoclonal Antibodies Disrupts Key Survival Pathways in Paediatric Burkitt’s Lymphoma Malignant B Cells.” Clinical & Translational Immunology 13 (10): 1–17. doi:10.1002/cti2.70011.